CasNo.1165910-22-4,LIGANDROL(LGD-4033),(1165910-22-4) Suppliers

10 Kilogram	FOB Price: USD 1.0000

Min.Order :10 Kilogram
Purity: >98%
Payment Terms : L/C,D/A,D/P,T/T,,MoneyGram

Keywords

SAMRS Product Specification : 98% Sample Requirement : Free Sample

Quick Details

Appearance:WHITE POWER
Application:lose weight Increasing bone mineral density
PackAge:5kg/bag,10kg/bag or as demand
ProductionCapacity:500|Kilogram|Month
Storage:contact us
Transportation:

Superiority:

excellent promotion

Details:

Product Introduction

What is LIGANDROL(LGD-4033)

LGD-4033 is a selective androgen receptor modulator (SARMS), and a novel non-steroidal oral SARM that binds to AR with high affinity (Ki of ~1 nM) and selectivity. It’s in a class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.

How it works

LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds to the androgen receptor with high affinity and selectivity. It demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands. LGD-4033 has recently completed a Phase I Multiple Ascending Dose study in healthy volunteers.

Dosages and Suggestion

Recommended maximum dose LIGANDROL the safety and tolerability up to doses of 22 mg -25mg . It has a half-life of 24 hours a day.

SARMS We offer

AICAR	2627-69-2	acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown
MK2866	841205-47-8	medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy.
MK-677	15972-10-0	A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly
LGD-4033	1165910-22-4	pharmacological profile similar to that of enobosarm, Ostarine,MK-2866
GW1516	317318-70-0	For obesity, diabetes, dyslipidemia and cardiovascular disease
Andarine(S4)	401900-40-0	partial agonist, intended mainly for treatment of benign prostatic hypertrophy
SR9009	1379686-30-2	under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice
SR9011	1379686-30-2	For obesity, diabetes, dyslipidemia and cardiovascular disease
RAD140	1182367-47-0	New generation for gaining mass and cutting edges
YK11	366508-78-3 431579-34-9	a SARM and myostatin inhibitor in one
GHRP-2	158861-67-7	Growth Hormone Releasing Peptide-2
GHRP-6	87616-84-0	Growth Hormone Releasing Peptide-6
TB500	107761-42-2	Thymosin beta 4
SM130,686	/	/